copyrighted by the atlanta journal constitution 2005

copyrighted by the associated press 2005

www.ajc.com

New Prostate Cancer Treatment Promising
By MARILYNN MARCHIONE
AP Medical Writer

ORLANDO, Fla. - Doctors are reporting their first success at
improving survival in men with advanced prostate cancer by using a
treatment that trains the immune system to fight tumors. The approach
is called a cancer vaccine although unlike traditional vaccines, it
treats disease rather than prevents it.

In a study of 127 men with advanced prostate cancer, those who got the
vaccine lived an average of 4 1/2 months longer than those who were
given fake treatments. After three years, survival was 34 percent in
the vaccine group and only 11 percent in the other.

(enlarge photo)
Doctors are reporting their first success at improving survival in men
with advanced prostate cancer by using a treatment that trains the
immune system to fight tumors. (AP Graphic)
"That's a huge difference. These are people who have relatively few
options, with limited survival," said Dr. Eric Small of the University
of California in San Francisco, who led the study and will give results
at a first-of-its-kind prostate cancer research meeting that opens
Thursday in Orlando.

The meeting is intended to bring more muscle to fighting the disease,
which is the most common non-skin cancer in American men. About 230,000
new cases and 30,000 deaths from it are expected this year.

The vaccine, called Provenge, doesn't work like chemotherapy, and its
side effects typically are only a couple days of fevers and chills,
like what people feel when they are fighting off a cold.

The vaccine combines a protein found in most prostate cancers with a
substance that helps specialized immune system cells recognize cancer
as a threat, just as they recognize and confront germs that enter the
body.

The treatment is customized for each patient. Doctors collect these
cells from a patient's blood, mix them with the vaccine, and then give
the concoction back to the patient in three infusions over a month.

In the study, men treated with Provenge survived an average of 26
months compared with 21.4 months for those who received dummy vaccine.
After three years, 28 of the 82 men who got vaccine were alive but only
five of the 45 in the placebo group were.

"This is provocative, it is promising. We now need to confirm this with
an independent study," said Dr. Philip Kantoff, a Harvard Medical
School professor who heads prostate cancer treatment at the Dana-Farber
Cancer Institute in Boston. He was not involved in the study.

He and other specialists noted that the study didn't achieve its
primary goal of delaying the time when men's disease worsened -
something that could be expected if the vaccine were truly helping men
live longer.

"Time to progression is interesting but it isn't the gold standard. The
gold standard is survival. We've improved survival," Small countered.

Neither Small nor Kantoff has any financial ties to the vaccine or its
maker, Seattle-based Dendreon Corp.

If a second study in about 100 men gives similar results later this
year, Dendreon will seek Food and Drug Administration approval for
Provenge, which already is being fast-tracked by the agency, said the
company's president, Dr. Mitchell Gold.

Dendreon also is testing Provenge for less serious cases of prostate
cancer. Partial results from one such study are to be presented at the
meeting on Saturday.

"We see it moving into earlier and earlier stages of disease," Gold
said of Provenge.

Another Dendreon vaccine, Neuvenge, is being tested for advanced breast
cancer. A very large nationwide study also is testing a different type
of cancer vaccine for the deadly skin cancer melanoma.

Dr. Durado Brooks, who heads prostate cancer research for the American
Cancer Society, said Dendreon's vaccine is the farthest along for
prostate cancer.

"Is it ready for market? I don't know," he said, but called the new
results encouraging.

___

February 17, 2005 - 11:23 a.m. EST

Copyright 2005, The Associated Press. The information contained in the
AP Online news report may not be published, broadcast or redistributed
without the prior written authority of The Associated Press.